Single-dose palonosetron and dexamethasone in preventing nausea and vomiting induced by moderately emetogenic chemotherapy in breast and colorectal cancer patients

Tumori

Volumn 97, Issue 3, 2011, Pages 362-366

  Brugnatelli, Silvia ^a   Gattoni, Elisabetta ^a   Grasso, Donatella ^a   Rossetti, Franca ^a   Perrone, Tania ^b   Danova, Marco ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Scientific Department Italfamaco SpA   (Italy)

Author keywords

Chemotherapy inducing nausea and vomiting (CINV); Dexamethasone; Moderately emetogenic chemotherapy (MEC); Palonosetron

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PALONOSETRON;

ABDOMINAL PAIN; ADULT; AGED; ANTIEMETIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CONTROL; CANCER PATIENT; CANCER SURGERY; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; INSOMNIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; SIDE EFFECT; SINGLE DRUG DOSE; VITAL SIGN;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; DEXAMETHASONE; FEMALE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; PROSPECTIVE STUDIES; QUINUCLIDINES; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME; VOMITING;

EID: 79960864270     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/912.10035     Document Type: Article

References (29)

1. Naeim A, Sydney M, Lorenz KA, Sanati H, Walling A, Asch SM: Evidence-based recommendations for cancer nausea and vomiting. J Clin Oncol, 26: 3903-3910, 2008.
2. Hesketh PJ: Chemotherapy-induced nausea and vomiting. N Engl J Med, 358: 2482-2494, 2008.
3. Miguel R: Controlling chemotherapy-induced and postoperative nausea and vomiting. Cancer Control, 6: 393-397, 1999.
4. Roscoe JA, Hickok JT, Morrow GR: Patient expectations as predictor of chemotherapy-induced nausea. Ann Behav Med, 22: 121-126, 2000. (Pubitemid 32429376)
5. Ettinger DS, Armstrong DK, Barbour S, Berger MJ, Bierman PJ, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Markiewicz MA, Nabati L, Nesheiwat C, Rugo HS, Sorscher SM, Stucky-Marshal L, Todaro B, Urba SJ: Antiemesis. Clinical practice guidelines in oncology Natl Compr Canc Netw, 7: 572-595, 2009.
6. Roila F, Hesketh PJ, Herrstedt J; Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer: Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia International Antiemetic Consensus Conference. Ann Oncol, 17: 20-28, 2006. (Pubitemid 43033835)
7. Walton SM: Advances in use of the 5-HT3 receptor antagonists. Expert Opin Pharmacother, 1: 207-223, 2000.
8. Roila F, Ballatori E, Tonato M, Del Favero A: 5-HT3 receptor antagonists: differences and similarities. Eur J Cancer, 33: 1364-1370, 1997. (Pubitemid 27404891)
9. Aapro MS: Palonosetron as an anti-emetic and anti-nausea agent in oncology. Ther Risk Clin Manag, 3: 1009-1020, 2007.
10. Rojas C, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J, Rubenstein E, Sebastiani S, Cantoreggi S, Snyder SH, Slusher B: Palonosetron exhibits uniquemolecular interactions with the 5-HT3 receptor. Anesth Analg, 107: 469-478, 2008. Erratum in: Anesth Analg, 107: 1405, 2008.
11. Rojas C, Thomas AG, Alt J, Stathis M, Zhang J, Rubenstein EB, Sebastiani S, Cantoreggi S, Slusher BS: Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol, 626: 193-199, 2010.
12. Ioannidis JP, Hesketh PJ, Lau J: Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. J Clin Oncol, 18: 3409-3422, 2000.
13. Roila F, Warr D, Clarck-Snow RA, Tonato M, Gralla RJ, Einhorn LH, Herrstedt J: Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer, 13: 104-108, 2005. (Pubitemid 40558165)
14. Grunberg SM: Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol, 18: 233-240, 2007.
15. Vardy J, Chiew KS, Galica J, Pond GR, Tannock IF: Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer, 94: 1011-1015, 2006.
16. Gralla R, Lichinitser M, Van der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M: Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol, 14: 1570-1577, 2003. (Pubitemid 37304615)
17. Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A: A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol, 17: 1441-1449, 2006. (Pubitemid 44400384)
18. Eisenberg P, Figuero-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S; 99-04 Palonosetron Study Group: Improved prevention of moderately emetogenic chemotherapy induced nausea and vomiting with palonosetron, a pharmacologically novel 5HT3 receptor antagonist. Results of a phase III, single dose trial versus dolasetron. Cancer, 98: 2473-2482, 2003. (Pubitemid 37466663)
19. Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S: Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol, 10: 115-124, 2009.
20. Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM: Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol, 15: 103-109, 1997. (Pubitemid 27020563)
21. Fleming TR: One sample multiple testing procedure for phase II clinical trials. Biometrics, 38: 143-151, 1982.
22. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D, on behalf of the ESMO/MASCC Guidelines Working Group: Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy- induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol, 21 (Suppl 5): v232-v243, 2010.
23. Aapro M, Fabi A, Nolè F, Medici M, Steger G, Bachmann C, Roncoroni S, Roila F: Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol, 21: 1083-1088, 2010.
24. Celio L, Frustaci S, Denaro A, Buonadonna A, Ardizzoia A, Piazza E, Fabi A, Capobianco AM, Isa L, Cavanna L, Bertolini A, Bichisao E, Bajetta E, for the Italian Trials in Medical Oncology Group: Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting followingmoderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer, Jun 25 [Epub ahead of print], 2010.
25. Yin L, Li YB, Wang YS: Dexamethasone-induced adipogenesis in primary marrow stromal cell cultures: mechanism of steroid-induced osteonecrosis. Chin Med J (Engl), 119: 581-588, 2006. (Pubitemid 43796864)
26. Aapro MS, Walko CM: Aprepitant: drug-drug interactions in perspective. Ann Oncol, 21: 2316-2323, 2010.
27. Jakobsen JN, Herrstedt J: Prevention of chemotherapy-induced nausea and vomiting in elderly cancer patients Crit Rev Oncol Hematol, 71: 214-221, 2009.
28. Giuliani F, Cilenti G, Nugnes I, Maiello E, Di Bisceglie M, Lorusso V, Adamo V, Colucci G: Palonosetron for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic adjuvant folfox-4 regimen in colorectal cancer (CRC) patients: a phase II study of the Gruppo Oncologico dell'ItaliaMeridionale (GOIM). Eur J Cancer Suppl, 6: 102-106, 2008.
29. Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, Siebel M: Effectiveness of a singleday three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer, 17: 589-594, 2009.